Also found in: Medical.
LDL-CLow Density Lipoprotein-Cholesterol
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
We are also encouraged by the guidelines' reaffirmation of the 'compelling evidence that LDL-C is causally associated with the risk of ASCVD, and that lowering LDL-C reduces the risk of ASCVD proportionally to the absolute achieved reduction in LDL-C.' Data provide 'strong support for the concept that LDL particles have both a causal and cumulative effect on the risk of ASCVD.
ORION-11 is a pivotal Phase 3, placebo-controlled, double-blind, randomised study to evaluate the efficacy, safety, and tolerability of inclisiran sodium 300 mg administered subcutaneously in 1,617 patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents and elevated LDL-C despite maximum tolerated dose of statin therapy (with or without ezetimibe).
In the AIS group, mean age (68.5[+ or -]12.6 vs 61.2[+ or -]4.2; p<0.001), systolic blood pressure (p<0.001), blood glucose (p<0.001), TG (p<0.001), TC (p<0.001), and LDL-C (p<0.001) were significantly higher compared with the control group, while HDL-C (p<0.001) was significantly lower in AIS patients.
It has been demonstrated in numerous studies that many high risk patients do not attain desired LDL-C control in spite of being treated with intensive statin therapy.
Our previous study demonstrated a higher level of LDL-C in AMI cases compared with controls.[5] In the present study, we found that AMI patients also showed higher ratios of LDL-C/HDL-C (median [IQR]: 2.95 [2.51, 3.92] vs.
Despite accumulating evidence in favor of apoB, guidelines continue to focus solely on LDL-C. When comparing the 2 biomarkers, it is important to note that LDL-C is not a specific molecule, nor has it been consistently defined or measured.
However, these later measures of risk depiction i.e., LDL-c and non-HDL-c are not included or related with components of MS or underlying IR.
Patients with a total deficiency of PCSK9 have been reported to have LDL-C levels in the range of 15 mg/dl without having any adverse effects from these extremely low LDL levels [12].
in 2010 (2) reviewed 26 clinical trials which included nearly 170,000 participants and showed a relative risk reduction in total mortality of 10% per 1 mmol/L reduction in LDL-C with a p value < 0.001.
Laura D'Erasmo from Sapienza University of Rome carried out the study, which found higher reductions in LDL-C were recorded in the 15 patients with HoFH treated with Lojuxta than had been achieved with any other drug or intervention.
About 73.5 million (31.7%) adults in America have high levels ([greater than or equal to] 130 mg/dL) of low-density lipoprotein cholesterol (LDL-C), which is a causative factor for myocardial infarction, ischemic stroke, and cardiovascular death (1).